An observational study in Anal Canal Cancer, sponsored by Institut Paoli-Calmettes. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-14.
Sponsored by Institut Paoli-Calmettes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Comparative retrospective study of two anal canal brachytherapy techniques aimed at boosting [low dose rate (LDR) and high dose rate (HDR)]
Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate, Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.
33 studies on the registry are indexed under Anal Canal Carcinoma; 8 are open to participants now.
Browse Anal Canal Carcinoma studies →Institut Paoli-Calmettes is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated with anal canal brachytherapy for boost, between 2008 and 2016.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
Radiation: Brachytherapy
Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
Radiation: Brachytherapy
Brachytherapy
Evaluation of the efficacy of interstitial brachytherapy of the anal canal
Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate
Time frame: 1 year
Evaluation of the tolerance of interstitial brachytherapy of the anal canal
Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.
Time frame: 1 year
Estimation of local control
Local control defined as the time between the date of diagnosis and the date of local relapse or death or recent news
Time frame: 1 year
Estimation of disease free survival
Disease free survival defined as the delay between the date of diagnosis and the date of local or locoregional or distant relapse or death or recent news
Time frame: 1 year
Estimation of overall survival
Overall survival defined as the time between the date of diagnosis and the date of death or latest news
Time frame: 1 year
Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups
rate of toxicities
Time frame: 1 year
Plan to share: No
Ran from Aug 2007 to primary completion in Jul 2016, 107 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.